Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

ORLANDO -- Stem-cell transplants with mismatched unrelated donors (MMUDs) beyond a single HLA locus (<7/8) had 1-year survival similar to better-matched donors, suggesting significant potential to ...

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic intervention for a variety of haematological malignancies and non-malignant disorders. Central to the success of HSCT is ...

“Since the discovery of transplantation as a life-saving therapy for blood malignancies by Dr. E Donnall Thomas, there have been major advances that have significantly lowered the side effects and ...

When a patient undergoes an organ transplant, failure to match the donor and recipient can lead to the recipient's immune system attacking the new organ, a process triggered by a specific HLA (human ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Primarily, the transplantation from a ...

Analyses of two large stem-cell transplant registries yielded conflicting results about the effect of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis on the ...

HLA matching in bone marrow transplantation has an important role in determining successful outcome. However HLA typing of both potential related and unrelated donors can be both time-consuming and ...